1-4 of 4
Alberto Franzin
Close
Sort by
Journal Articles

Reprogramming Macrophages Using Autologous Hematopoietic Stem Cells As Immunotherapy for Glioblastoma: TEM-GBM Study (NCT03866109)

Francesca Farina, Bernhard Gentner, Gaetano Finocchiaro, Marica Eoli, Alessia Capotondo, Elena Anghileri, Matteo Barcella, Valentina Brambilla, Maria Grazie Bruzzone, Matteo Giovanni Carrabba, Valeria Cuccarini, Giorgio D'Alessandris, Francesco Di Meco, Valeria Ferla, Alberto Franzin, Paolo Ferroli, Filippo Gagliardi, Federico Legnani, Stefania Mazzoleni, Pietro Mortini, Matteo Maria Naldini, Alessandro Olivi, Roberto Pallini, Monica Patanè, Rosina Paterra, Bianca Pollo, Marco Saini, Silvia Snider, Andrew Zambanini, Luigi Naldini, Carlo Russo, Fabio Ciceri
Journal: Blood
Blood (2022) 140 (Supplement 1): 4575–4576.
https://doi.org/10.1182/blood-2022-165975
Published: 2022
Journal Articles

Clinical Relevance of the Dose of Cytarabine In the Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Chemotherapy Combination

Andrés JM Ferreri, MD, Giada Licata, Marco Foppoli, Gaetano Corazzelli, Emanuele Zucca, Caterina Stelitano, Francesco Zaja, Sergio Fava, Rossella Paolini, Alberto Franzin, Letterio Politi, Maurilio Ponzoni, MD, Michele Reni
Journal: Blood
Blood (2010) 116 (21): 1780.
https://doi.org/10.1182/blood.V116.21.1780.1780
Published: 2010
Journal Articles

Post-Chemotherapy Brain Irradiation in Primary CNS Lymphomas: Impact on Survival of Different Fields and Doses.

Andres JM Ferreri, Chiara Verona, Letterio Salvatore Politi, Lucia Perna, Anna Chiara, Marco Foppoli, Giada Licata, Silvia Mappa, Fabio Ciceri, Piero Picozzi, Alberto Franzin, Silvia Govi, Maurilio Ponzoni, MD, Maria Rosa Terreni, Eugenio Villa, Michele Reni, M.D.
Journal: Blood
Blood (2009) 114 (22): 2696.
https://doi.org/10.1182/blood.V114.22.2696.2696
Published: 2009
Journal Articles

Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis

Andres JM Ferreri, MD, Michele Reni, M.D., Marco Foppoli, M.D., Maurizio Martelli, M.D., Marina Siakantaris, M.D., Maurizio Frezzato, M.D., Maria Giuseppina Cabras, M.D., Alberto Fabbri, M.D., Gaetano Corazzelli, M.D., Fiorella Ilariucci, M.D., Giuseppe Rossi, M.D., Riccardo Soffietti, M.D., Caterina Stelitano, M.D., Daniele Vallisa, M.D., Francesco Zaja, M.D., Marta Gelemur, M.D., Gian Marco Aondio, M.D., Giuseppe Avvisati, M.D., Monica Balzarotti, MD, Alba Brandes, M.D., Maria Joao Costa, MD, Henry Gomez, M.D., Attilio Guarini, M.D., Graziella Pinotti, M.D., Luigi Rigacci, M.D., Catrina Uhlmann, M.D., Maria Angelopoulou, M.D., Maria Tirindelli, M.D., Virginia Naso, M.D., Alberto Franzin, M.D., Nicoletta Anzalone, M.D., Maurilio Ponzoni, M.D., Emanuele Zucca, M.D., Federico Caligaris- Cappio, M.D., Franco Cavalli, M.D.
Journal: Blood
Blood (2008) 112 (11): 580.
https://doi.org/10.1182/blood.V112.11.580.580
Published: 2008